Dorx

Dorx is a pre-clinical stage biotechnology company focused on developing novel small molecule therapeutics targeting the CXCR4 pathway. The company's primary mission is to address unmet needs in oncology and inflammatory diseases by modulating the C-X-C chemokine receptor type 4, which plays a critical role in tumor growth, metastasis, and immune cell trafficking. Dorx is leveraging its proprietary platform to design highly selective and potent inhibitors that can be used as monotherapies or in combination with existing standard-of-care treatments. The company aims to advance its lead candidates into clinical trials to provide new options for patients with refractory or metastatic cancers.